Riyaz Shah, Consultant Medical Oncologist at Cromwell Hospital, shared a post on X:
“Great to see Encorafenib binimetinib reimbursed in NHS England for BRAF V600E NSCLC.
- Note; V600E restriction in both E+B and D+T.
- Note; 1st line only.
- Note; can switch from D+T to E+B for toxicity early on. FYI We pick these up on COBAS often before ctDNA or tissue NGS.”
Other articles featuring Riyaz Shah on OncoDaily.
